Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight

News provided by

Sep 19, 2022, 11:30 ET

The ADPKD market size is expected to grow positively owing to the increasing diagnosed prevalence, development of well-designed, randomized, controlled non-crossover trials with the potential benefits for ADPKD patients and others. In addition, the approval and entry of new drugs will change the ADPKD market dynamics in the future.

LAS VEGAS, Sept. 19, 2022 /PRNewswire/ -- DelveInsight's ADPKD Market Insights report includes a comprehensive understanding of current treatment practices, ADPKD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the ADPKD Market Report

As per DelveInsight estimates, the ADPKD market size in the 7MM was approximately USD 1,077 million in 2021.
As per our analysis, the total ADPKD diagnosed prevalent cases in the 7MM were approximately 367K in 2021.
Leading ADPKD companies such as Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others are developing novel ADPKD drugs that can be available in the ADPKD market in the upcoming years.
The promising ADPKD therapies in the pipeline include GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and others.
The ADPKD market size is expected to boost due to the anticipated launch of potential therapies and an increase in the diagnosed prevalent population of ADPKD in the 7MM.

Discover which therapies are expected to grab major ADPKD market share @ADPKD Market Report

ADPKD Overview

Autosomal dominant polycystic kidney disease also called "adult PKD," is the most common inherited kidney disorder characterized by cyst growth in the kidneys, which increases with disease progression and results in renal failure. ADPKD is a heterogeneous monogenetic disorder caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene located on chromosome 4.

In many cases, ADPKD does not manifest itself until cysts are half an inch or greater in size. The most common ADPKD symptoms are back pain, pain between the ribs and hips, and headaches, and the pain might be acute or chronic, minor or severe.

ADPKD Epidemiology Segmentation

DelveInsight estimates that there were approximately 367K ADPKD diagnosed prevalent cases in the 7MM in 2021.

Among the EU5 countries, the UK recorded the highest diagnosed prevalence of ADPKD in 2021.

The ADPKD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of ADPKD
Age-specific Cases of ADPKD
Mutation-specific Cases of ADPKD

Download the report to understand which factors are driving ADPKD epidemiology trends @ADPKD Epidemiological Insights

ADPKD Treatment Market

There is currently no cure for PKD. However, extensive research is being conducted. Recent research suggests that drinking plain water throughout the day and avoiding caffeine-containing beverages can help to slow cyst growth. Research is also assisting us in better understanding the genetic basis of PKD.

Individuals with ADPKD are treated by paying close attention to diet, fluid intake, blood pressure control, and avoiding harmful drug and lifestyle choices. Implementing these measures early in the disease should slow the progression of kidney (renal) disease and, to some extent, preserve kidney function.

A coordinated effort of a team of specialists working together to systematically and comprehensively plan an affected individual's prescription is required to treat ADPKD effectively. Primary care family physicians, pediatricians, or internists who collaborate with physicians specializing in kidney disorders (nephrologists), surgical disorders of the urinary tract (urologists), dietitians, and other health care Professionals are examples of such specialists. Affected individuals and their families may benefit from genetic counseling.

Otsuka Pharmaceuticals' tolvaptan (Jynarque/Jinarc/Samsca) is the only approved drug in the world for treating adults with ADPKD. Adults at risk of rapidly progressing ADPKD inhibit vasopressin receptors in the kidneys and slow kidney function decline by lowering adenylate cyclase activity.

In addition, in collaboration with the Mario Negri Institute for Pharmacological Research in Italy, Otsuka has conducted trials to evaluate the efficacy of tolvaptan plus octreotide LAR combination therapy, a vasopressin antagonist and somatostatin analog combination, in ADPKD patients with normal or hyperfiltration kidney function.

To know more about the treatment for ADPKD, visit @ADPKD Management

ADPKD Pipeline Therapies and Key Companies

Tesevatinib/KD019: Sanofi
Bardoxolone methyl: Reata Pharmaceuticals
GLPG2737: Galapagos NV
AT-20494: Janssen Pharmaceuticals
RGLS8429: Regulus Therapeutics
XRx-008: Xortx Therapeutics

Learn more about the ADPKD therapies in clinical trials @Drugs for ADPKD Treatment

ADPKD Market Dynamics

Technological advances in diagnostic procedures, as a result of a greater emphasis on early diagnosis, have reduced undiagnosed cases. Thus persistently rising cases of diagnosed ADPKD provide opportunities for companies to launch new therapies in the ADPKD market.

Moreover, advances are being made in determining the genetic causes of ADPKD, non-invasive monitoring, and in predicting disease progression, all of which will aid in disease management. Additionally, pre-symptomatic diagnosis and its application in the care and management of ADPKD patients also contribute to the growth of the ADPKD market.

Furthermore, the ADPKD pipeline is robust and dynamic, with many products being developed across different stages for ADPKD, thereby bolstering the growth of the ADPKD market. In addition, the discovery of biomarkers for early detection of ADPKD patients at high risk of progression will aid in better managing ADPKD patients and preventing disease progression.

However, there are not many large-scale clinical trials being conducted to study drugs to treat ADPKD, and several have failed, thus hampering the ADPKD market growth. Moreover, most ADPKD studies have been conducted in adults, and their findings are not always easily transferable to children.

Treatment discontinuation due to inability to tolerate aquaretic agents, hepatic adverse events (abnormal liver function tests), disease progression, and acute kidney injury. Furthermore, lack of awareness and limited knowledge of ADPKD among the patients and primary care physicians are noticeable shortcomings in the ADPKD market, which need to be addressed.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Base Year	2021
Market CAGR	14.5 %
Market Size in 2021	1.07 Billion
Key ADPKD Companies	Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others
Key ADPKD Therapies	GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and others

Scope of the ADPKD Market Report

Therapeutic Assessment: ADPKD current marketed and emerging therapies
ADPKD Market Dynamics: ADPKD market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, ADPKD Market Access and Reimbursement

Discover more about ADPKD medications in development @ADPKD Clinical Trials

Table of Contents

1.	ADPKD Market Key Insights
2.	ADPKD Market Report Introduction
3.	ADPKD Market Overview at a Glance
4.	ADPKD Market Executive Summary
5.	Disease Background and Overview
6.	ADPKD Treatment and Management
7.	ADPKD Epidemiology and Patient Population
8.	Patient Journey
9.	ADPKD Marketed Drugs
10.	ADPKD Emerging Drugs
11.	7MM ADPKD Market Analysis
12.	ADPKD Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	ADPKD Market Drivers
16.	ADPKD Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Get in touch with our Business executive @Healthcare Due Diligence Services

Related Reports

ADPKD Epidemiology

ADPKD Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted ADPKD epidemiology in the 7MM.

ADPKD Pipeline

ADPKD Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ADPKD companies, including Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, among others.

Polycystic Kidney Disease Market

Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycystic kidney disease companies, including Abbott, Exelixis, Amgen, Galapagos, among others.

Polycystic Kidney Disease Pipeline

Polycystic Kidney Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key polycystic kidney disease companies, including Abbott, Exelixis, Amgen, Galapagos, among others.

Polycystic Kidney Disease Epidemiology

Polycystic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted polycystic kidney disease epidemiology in the 7MM.

Other Trending Reports

Browse through our latest blog on ADPKD Treatment Landscape to get more detailed insights

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP